ETDETA ETDETA
section 301 Published 2026-06-24

Initiation of Section 301 Investigation; Hearing; and Request for Public Comments: Germany's Persistent Underpayment for Innovative Pharmaceutical Products

Origins: DE
📌 ETDETA brief — importer impact summary (educational)

Brief takeaway: The USTR has opened a Section 301 investigation into Germany's alleged underpayment for innovative pharmaceutical products, but no tariffs or trade actions have been imposed at this stage.

What changed: According to the notice, the U.S. Trade Representative has initiated an investigation under the Trade Act of 1974 regarding Germany's persistent underpayment for innovative pharmaceutical products. The notice states that the inter-agency Section 301 Committee is holding a public hearing and requesting public comments in connection with the investigation.

Who's affected: The notice names Germany (DE) as the country whose practices are under investigation, and cites innovative pharmaceutical products as the subject area. The notice does not specify particular HTS chapters, codes, tariff rates, or products that would be subject to any future action.

What to review:
- Review whether your imports involve pharmaceutical products connected to Germany, since the investigation focuses on that origin and sector.
- Check the notice for the public hearing date and comment submission deadlines if you wish to participate in the process.
- Confirm with your customs broker or trade counsel whether to monitor this proceeding for any later proposed remedies, which are not part of this initiation notice.
- Review your supply-chain exposure to German-origin pharmaceutical inputs so you can respond if the investigation later leads to proposed measures.

This is general information, not legal advice and not a compliance determination — confirm specifics with a licensed customs broker or trade counsel.

Official notice

The United States Trade Representative (U.S. Trade Representative) has initiated an investigation pursuant to the Trade Act of 1974, as amended (Trade Act), with respect to Germany's persistent underpayment for innovative pharmaceutical products. The inter-agency Section 301 Committee is holding a public hearing and seeking public comments in connection with this investigation.
Source: Federal Register · Trade Representative, Office of United States · Read the official notice ↗

Check how this affects your product

Need help moving this shipment?

ETDETA coordinates the logistics side of your U.S. import — booking, ocean freight, inland transportation, and customs-clearance coordination through licensed customs brokers.

Get a Full Freight Quote →

Related updates

This update is a general educational summary based on public CBP CSMS / Federal Register information. It is not legal advice, customs broker advice, a final classification, duty determination, entry instruction, or compliance determination. Importers should confirm applicability, effective dates, HTSUS/Chapter 99 reporting, rates, refunds, PSC procedures, and filing instructions with their licensed customs broker, trade counsel, and/or CBP.